



New Drug Indications / Warnings September 2009

(New Drug Indications/Black Box Warnings: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2009			
Zoledronic Acid Injection Formulary Page: 8	Reclast	Endocrine Metabolic: Biphosphonates. <i>New indication for osteoporosis in men.</i>	Current: Reclast: Physician Consult/ Physician Initiated. 9/21/09: No Change
Spirolactone Formulary Pg. 13	Spirolactone, Aldactone	Renal and Genitourinary Agents: Diuretics: Potassium-Sparing Diuretics. <i>New indication for severe heart failure.</i>	Current: CTP holder may prescribe 9/21/09: No Change
Duloxetine Formulary Pg. 16	Cymbalta	Central Nervous System Agents: Antidepressants: Serotonin and Neorpinephrine Reuptake Inhibitors. <i>New indication for the management of fibromyalgia.</i>	Current: CTP holder may prescribe 9/21/09: No Change
June 2009			
Zoledronic Acid Injection Formulary Pg. 8	Reclast	Endocrine Metabolic: Biphosphonates: <i>New indication for glucocorticoid – inducing osteoporosis.</i>	Current: Physician Consult / Physician Initiated 9/21/09: No Change
Ergotamine Tartrate Oral Formulary Pg. 15	Ergomar	Central Nervous System Agents: Agents for Migraine: Ergotamine Derivatives. <i>Black box warning for serious and/or life-threatening peripheral ischemia with coadministration of ergotamine with potent CYP 3A4 inhibitors, including</i>	Current: CTP holder may prescribe 9/21/09: No Change

New Drug Indications/Black Box Warnings September 2009

<p>Ergotamine Tartrate Oral Formulary Pg. 15</p>	<p>Ergomar</p>	<p>Central Nervous System Agents: Agents for Migraine: Ergotamine Derivatives. <i>Black box warning for serious and/or life-threatening peripheral ischemia with coadministration of ergotamine with potent CYP 3A4 inhibitors, including protease inhibitors and macrolide antibiotics.</i></p>	<p>Current: CTP holder may prescribe 9/21/09: No Change</p>
<p>Fluoxetine Oral Formulary Pg. 16</p>	<p>Prozac, Sarafem, Selfemra</p>	<p>Central Nervous System Agent: Antidepressant: Selective Serotonin Reuptake Inhibitor. <i>New Indication for depressive episodes associated with bipolar 1 disorder. (fluoxetine and olanzapine in combination).</i></p>	<p>Current: CTP holder may prescribe 9/21/09: No Change</p>
<p>July 2009</p>			
<p>Olanzapine/Fluoxetine Hydrochloride Oral Formulary Pg. 16</p>	<p>Symbyax</p>	<p>Central Nervous System Agent: Miscellaneous Psychotherapeutic Agents: Psychotherapeutic Combinations. <i>New indication for treatment resistant depression.</i></p>	<p>Current: Physician Consultation/ Physician Initiation 9/21/09: No Change</p>
<p>August 2009</p>			
<p>None</p>			



New Drugs September 2009

(Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2009			
None			
June 2009			
Everolimus Oral Formulary Pg. 24	Afinitor	Antineoplastic Agents: Protein-Tyrosine Kinase Inhibitors: mTOR inhibitors. <i>Indication for the treatment of advanced renal cell carcinoma.</i>	9/21/09: CTP holder MAY NOT prescribe
July 2009			
Iloperidone Oral Formulary Pg. 16	Fanapt	Central Nervous System Agents: Antipsychotic Agents: Benzisoxazole Derivatives. <i>Indication for the treatment of schizophrenia.</i>	9/21/09: Psych CTP holder may prescribe. Initial 90 day review. Physician Initiated / Physician Consult for CTP holder other than Psych. Initial 90 day review.
Artemether/ Lumefantrine Oral Formulary Pg. 20	Coartem	Systemic Anti-Infectives: Antimalarial Preparations. <i>Indication for the treatment of malaria.</i>	9/21/09: CTP holder may prescribe
Golimumab Injection Formulary Pg. 21	Simponi	Biologic and Immunologic Agents: Immunologic Agents: Immunomodulators. <i>Indication for ankylosing spondylitis, psoriatic arthritis and rheumatoid arthritis.</i>	9/21/09: Physician Initiated/ Physician Consult
August 2009			
Tolvaptan Oral Formulary Pg. 9	Samsca	Endocrine/Metabolic: Vasopressin Receptor Antagonist. <i>Indication for hypervolemic and euvolemic</i>	9/21/09: Physician Initiated/ Physician Consult -

New Drugs September 2009

		<i>hyponatremia.</i>	Initiation to be done in institutional setting.
Besifloxacin Hydrochloride Ophthalmic Formulary Page 23	Besivance	Ophthalmic / Otic Agents: Antibiotics. <i>Indication for bacterial conjunctivitis.</i>	9/21/09: CTP holder may prescribe



Formulary Revision Request September 2009

(Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
Formulary Review Revision Request from Susan Busch, MSN, CNP; Riana Naude, CNP; Doreen Papjick; Joan Luthanen, CNP; Amy Hazel, CNP; Tamara Cromiley, CNP; Ruth Mundy, CNP			
Cinacalet Formulary Pg. 10	Sensipar	Endocrine and Metabolic Agent: Calcium Receptor Agonist. <i>Indications for secondary hyperparathyroidism and parathyroid carcinoma.</i> Requesting change to CTP holder may prescribe.	Current: Physician Initiated/ Physician Consult 9/21/09: No Change
Formulary Review /Revision Request from Molly Stenger CPNP; Michelle Widecan CPNP; Rachael Ekstrand CPNP; Karen Ford, CPNP; Michelle Schrand CPNP, Angela Brown CPNP; Anika Surratt, CPNP; Kristina Kaufmann, CPNP			
Topical Lidocaine, Epinephrine and Tetracaine Anesthetic Formulary Pg. 22		Dermatologic Agents: Local Anesthetics, topical. <i>Indication skin disorders.</i> Requesting clarification that this includes topical local anesthetics which contain epinephrine.	Specific compound not listed. Local anesthetics, topical - Current: CTP holder may prescribe. 9/21/09: CTP holder may prescribe.
Formulary Review/Revision Request from Tracey Herstich, MSN, CNP			
Midazolam Formulary Pg. 16	Versed	Central Nervous System Agents: General Anesthetics. <i>Indications preoperative sedation and sedation/anesthesia.</i> Requesting change to Physician Initiated for Acute Care CTP holders.	Current: CTP may prescribe only oral and nasal route. 9/21/09: No Change

Formulary Review / Revision Request from Cheryl Ann Wall, RN, MS, CNP			
Riluzole Formulary Pg. 18	Rilutek	Central Nervous System Agents: Riluzole. <i>Indication for amyotrophic lateral sclerosis.</i> Requesting change to CTP holder may prescribe.	Current: CTP may not prescribe. 9/21/09: Physician Initiated/ Physician Consult
Formulary Review / Revision Request from Amy E. Miller, CNP			
Aripiprazole Formulary Pg. 16	Abilify	Central Nervous System Agents: Quinolone Derivatives. <i>Indications Bipolar disorder, major depressive disorder adjunctive treatment, schizophrenia</i> Requesting change to CTP holder may prescribe.	Current: Psych CTP holder may prescribe. CTP holder other than psych may not prescribe. 9/21/09: Psych CTP holder may prescribe. Initial 90 day review. Physician Initiated/ Physician Consult for CTP holder other than Psych. Initial 90 day review. Note: Aripiprazole will no longer be listed individually. The category will be incorporated in listing with other antipsychotic agents.
Crinuta V. Floruta CRNP and Catherine Holzheimer CNP; and Mary Kay Reinhardt, MSN, CNP			
Vancomycin Formulary Pg. 20	Vancocin	Anti-Infectives, Systemic: Vancomycin. <i>Indication for serious or severe infections not treatable with other</i>	Current: Physician Initiated / Physician Consult.

		<p><i>antimicrobials, including the penicillins and cephalosporins.</i></p> <p>Requesting change to CTP holder may prescribe initial dose as a pre-op antibiotic according to SCRIP guidelines.</p>	<p>9/21/09: CTP holder may prescribe within institutional setting ONLY for preoperative prophylaxis according to institutional protocol based on current national guidelines.</p> <p>For other indications remains Physician Initiation / Physician Consultation.</p>
<p>Formulary Review / Revision Request from Barbara Caldwell, CRNP et al and Carol A. Hall CRNP et al</p>			
<p>Metronidazole IV Formulary Pg. 20</p>	<p>Flagyl</p>	<p>Anti-Infectives, Systemic: Metronidazole. <i>Indications for anaerobic infections and prophylaxis preoperative, intraoperative and postoperative.</i></p> <p>Request CTP holder may prescribe any route.</p>	<p>Current: CTP holder may prescribe PO.</p> <p>9/21/09: CTP holder may prescribe.</p>